Sign up or Log In

-1 show sort by

You are not eligible to view 4 messages. To gain access to more recent message posts signup free for membership.

6	member 4/14/17 4:38PM Bear Case
How do you get comfortable with the terminal values of Copaxone and their generics business? Their lifecycle management of Copaxone has been truly incredible, but it appears like the jig may be up. Similarly, US generics... login to read the rest 1 view available tags
3	member 4/09/17 7:27PM Re: Re: Have you looked at Taro? 2
Taro basically provides no guidance and little look through but has a rock solid balance sheet and a likely takeover and is still very cheap despite the declining earnings. Plus it focuses on smaller dollar view available tags
2	member 4/09/17 5:32PM Re: Have you looked at Taro? 1
The consensus estimates I'm looking at have TEVA revenue more or less flat over the next two years, and EPS up slightly. TARO estimates have revenue declining 15%, and EPS down 25% (from $11.00/shr to... login to read the rest 3 view available tags